{"id":405803,"date":"2020-12-28T09:18:18","date_gmt":"2020-12-28T14:18:18","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=405803"},"modified":"2020-12-28T09:18:18","modified_gmt":"2020-12-28T14:18:18","slug":"exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\/","title":{"rendered":"Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day"},"content":{"rendered":"

<\/p>\n

Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day<\/b><\/p>\n

CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE<\/a>)–Exicure, Inc. (NASDAQ: XCUR)<\/b>, the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA\u2122) technology, announced that it will host a virtual R&D Day on Thursday, January 7th<\/sup>, 2021 from 09:00 am to 10:30 am ET to discuss Exicure\u2019s neuroscience pipeline, including its lead program for Friedreich\u2019s Ataxia which has progressed into IND-enabling studies.\n<\/p>\n

\nExicure\u2019s Scientific Advisory Board member Dr. Susan Perlman and the CEO of the Friedreich\u2019s Ataxia Research Alliance (FARA) Jennifer Farmer, will join Exicure\u2019s leadership team in discussing the company\u2019s progress in Friedreich\u2019s Ataxia and its expanding neuroscience pipeline.\n<\/p>\n

\nSusan L. Perlman, MD, is a Clinical Professor in the Department of Neurology at the David Geffen School of Medicine at UCLA, where she is also the Director of Clinical Trials and Director, Ataxia Clinic for UCLA\u2019s Neurogenetics program. She is a member of the Medical Research Advisory Board for the National Ataxia Foundation and has been a primary investigator for several Friedreich\u2019s Ataxia trials.\n<\/p>\n

\nJennifer Farmer, MS is the CEO of the Friedreich\u2019s Ataxia Research Alliance (FARA). Since joining FARA in 2006, she has led FARA\u2019s efforts to establish clinical research infrastructure and clinical trial readiness, grown the research grant program, and led efforts to engage bio-pharmaceutical companies in drug discovery and development for Friedreich\u2019s Ataxia.\n<\/p>\n

\nA live webcast will be available in the Events and Presentations section of Exicure\u2019s website on January 7, 2021 at 09:00 am ET. An archived version will be available on the company website following the event. Additional information can be found here: https:\/\/troutaccess.com\/index.php\/c\/ExicureResearchDay2021<\/a><\/p>\n

About Exicure, Inc.<\/b><\/p>\n

\nExicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN an SNA\u2013based therapeutic candidate, for the treatment of Friedreich\u2019s ataxia (FA). Exicure’s drug candidate AST-008 is currently in a Phase 1b\/2 clinical trial in patients with advanced solid tumors. Exicure is in Chicago, IL and has an office in Cambridge, MA.\n<\/p>\n

\nFor more information, visit Exicure\u2019s website at www.exicuretx.com<\/a>.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20201228005178\/en\/<\/a><\/span><\/p>\n

For Media:
\n<\/b>
Karen Sharma
\n
MacDougall
\n
781-235-3060
\n
ksharma@macbiocom.com<\/a><\/p>\n

KEYWORDS:<\/b> Illinois Massachusetts United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Research Infectious Diseases Genetics Other Health Biotechnology General Health Pharmaceutical Health Science Other Science<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA\u2122) technology, announced that it will host a virtual R&D Day on Thursday, January 7th, 2021 from 09:00 am to 10:30 am ET to discuss Exicure\u2019s neuroscience pipeline, including its lead program for Friedreich\u2019s Ataxia which has progressed into IND-enabling studies. Exicure\u2019s Scientific Advisory Board member Dr. Susan Perlman and the CEO of the Friedreich\u2019s Ataxia Research Alliance (FARA) Jennifer Farmer, will join Exicure\u2019s leadership team in discussing the company\u2019s progress in Friedreich\u2019s Ataxia and its expanding neuroscience pipeline. Susan L. Perlman, MD, is a Clinical Professor in the Department of … <\/p>\n

Continue reading “Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-405803","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nExicure Provides Neuroscience Pipeline Update at Virtual R&D Day - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA\u2122) technology, announced that it will host a virtual R&D Day on Thursday, January 7th, 2021 from 09:00 am to 10:30 am ET to discuss Exicure\u2019s neuroscience pipeline, including its lead program for Friedreich\u2019s Ataxia which has progressed into IND-enabling studies. Exicure\u2019s Scientific Advisory Board member Dr. Susan Perlman and the CEO of the Friedreich\u2019s Ataxia Research Alliance (FARA) Jennifer Farmer, will join Exicure\u2019s leadership team in discussing the company\u2019s progress in Friedreich\u2019s Ataxia and its expanding neuroscience pipeline. Susan L. Perlman, MD, is a Clinical Professor in the Department of … Continue reading "Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-28T14:18:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201228005178r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day\",\"datePublished\":\"2020-12-28T14:18:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\\\/\"},\"wordCount\":476,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201228005178r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\\\/\",\"name\":\"Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201228005178r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2020-12-28T14:18:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201228005178r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201228005178r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\/","og_locale":"en_US","og_type":"article","og_title":"Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day - Market Newsdesk","og_description":"Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA\u2122) technology, announced that it will host a virtual R&D Day on Thursday, January 7th, 2021 from 09:00 am to 10:30 am ET to discuss Exicure\u2019s neuroscience pipeline, including its lead program for Friedreich\u2019s Ataxia which has progressed into IND-enabling studies. Exicure\u2019s Scientific Advisory Board member Dr. Susan Perlman and the CEO of the Friedreich\u2019s Ataxia Research Alliance (FARA) Jennifer Farmer, will join Exicure\u2019s leadership team in discussing the company\u2019s progress in Friedreich\u2019s Ataxia and its expanding neuroscience pipeline. Susan L. Perlman, MD, is a Clinical Professor in the Department of … Continue reading \"Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-28T14:18:18+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201228005178r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day","datePublished":"2020-12-28T14:18:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\/"},"wordCount":476,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201228005178r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\/","name":"Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201228005178r1&sid=flmnd&distro=nx&lang=en","datePublished":"2020-12-28T14:18:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201228005178r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201228005178r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-provides-neuroscience-pipeline-update-at-virtual-rd-day\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/405803","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=405803"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/405803\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=405803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=405803"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=405803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}